Evidence map›Paper›PMID 25729327›Full record

ArticleCancer cell international2014

Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells.

Xinmiao Yang, Zeliang Shi, Ning Zhang, Zhouluo Ou, Shen Fu, Xichun Hu, Zhenzhou Shen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xinmiao YangDepartment of Radiation Oncology, Shanghai Jiao Tong University affiliated Sixth People's Hospital, 600 Yi Shan Road, Xuhui District Shanghai, 200233 China.
Zeliang ShiDepartment of Radiation Oncology, Shanghai Jiao Tong University affiliated Sixth People's Hospital, 600 Yi Shan Road, Xuhui District Shanghai, 200233 China.
Ning ZhangDepartment of Medical Oncology, Minhang Branch of Fudan, University Shanghai Cancer Center, Shanghai, China.
Zhouluo OuDepartment of Breast Surgery, Breast Cancer Institute, Shanghai Cancer Center, Fudan University, Shanghai, China.
Shen FuDepartment of Radiation Oncology, Shanghai Jiao Tong University affiliated Sixth People's Hospital, 600 Yi Shan Road, Xuhui District Shanghai, 200233 China.
Xichun HuDepartment of Medical Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China.
Zhenzhou ShenDepartment of Breast Surgery, Breast Cancer Institute, Shanghai Cancer Center, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSuberoyl bis-hydroxamic acid (SBHA) is a histone deacetylase (HDAC) inhibitor and exerts anti-growth effects in several malignancies including breast cancer. Proteasome inhibitors such as Bortezomib and MG-132 constitute novel anticancer agents. In this study, we investigated the synergistic antitumour activity of SBHA in combination with proteasome inhibitors.

methodsMCF-7 and MDA-MB-231 breast cancer cells were treated with SBHA, Bortezomib, and MG-132 alone or in combination for 72 h. Cell proliferation, colony formation, apoptosis and gene expression changes were examined.

resultsSBHA, Bortezomib, and MG-132 alone significantly inhibited the proliferation and colony formation and induced apoptosis in MCF-7 and MDA-MB-231 cells. Combined treatment showed a good synergistic antitumour effect against breast cancer cells. The p53 protein level was significantly elevated by combined treatment with SBHA and proteasome inhibitors. Moreover, combined treatment increased the expression of Bax, Bcl-xS, and Bak and decreased the expression of Bcl-2. Combination of SBHA with proteasome inhibitors causes synergistic anticancer effects on breast cancer cells. The potential molecular mechanism may involve induction of p53 and modulation of the Bcl-2 family proteins.

conclusionThese findings warrant further investigation of the therapeutic benefits of combination of SBHA with proteasome inhibitors in breast cancer.

Indexed as

Anticancer therapyBcl-2 familyHistone deacetylaseProteasome inhibitionSynergism

Identifiers

PMID25729327
PMCPMC4342900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.